Analytical Quality by Design with the Lifecycle Approach: A Modern Epitome for Analytical Method Development

Open access

Abstract

Quality by Design is the methodical method to development concept that starts with the predefined objects. The method put emphasis on the process of development of a product, the control process, which is built on risk management and comprehensive knowledge of science. The concept of QbD applied to analytical method development is known now as AQbD (Analytical Quality by Design). Comprehension of the Analytical Target Profile (ATP) and the risk assessment for the variables that can have an impact on the productivity of the developed analytical method can be the main principles of the AQbD. Inside the method operable design region (MODR), the AQbD permits the movements of the analytical methods. This paper has been produced to discuss various views of analytical scientists, the comparison with conventional methods, and the phases of the analytical techniques.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. ICH Expert Working Group. International Conference on Harmonization (ICH) Tripartite guidelines ICHQ8(R2): Pharmaceutical Development. 2009. London.

  • 2. Zlota “Practical Approaches to Quality by Design (QbD) for Pharmaceutical Process Research Development and Manufacturing “Three-day course presented at ZLOTA Company LLC in conjunction with Scientific Update LLP http://www.scientificupdate.co.uk/training/scheduledtraining-courses/details/216-actical%20Approaches%20to%20Quality%20by%20Design%20for%20Pharmaceutical%20Process%20R.html’DandManufacturing.

  • 3. Phil JB John R Chris J Melissa HB Roman S Simon B. The development phase of an LC method using QbD principles. Journal of Separation Science.2010; 2: 2–8.

  • 4. Monika LJ Santosh RT. Implementation of QbD approach to the analytical method development and validation for the estimation of propafenone hydrochloride in tablet dosage form. Chromatography Research International. 2013; 2013:1-9.

  • 5. Ferreira AP Gamble JF Leane MM Park H Olusanmi D Tobyn M. Enhanced Understanding of Pharmaceutical Materials Through Advanced Characterisation and Analysis. AAPS PharmSciTech. 2018;19(8):3462-3480.

  • 6. Taevernier L Wynendaele E D Hondt M De Spiegeleer B. Analytical quality-by-design approach for sample treatment BSA-containing solutions. Journal of Pharmaceutical Analysis. 2015;5(1):27–32.

  • 7. USP Validation and verification expert panel. Proposed New USP General Chapter: The Analytical Procedure Lifecycle 〈1220〉. United State Pharmacopeial Convention (USP). Pharmacopeial forum. 2017;43 (1).

  • 8. Zhang L Shirui M. Application of quality by design in the current drug development. Asian Journal of Pharmaceutical Sciences.2017;12:1–8.

  • 9. Pallagi E Ambrus R Szabó-Révész P Csóka I. Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation. Int J Pharm. 2015;491(1-2):384-92.

  • 10. Peraman R Bhadraya K Padmanabha RY. Analytical Quality by Design: A Tool for Regulatory Flexibility and Robust Analytics. International Journal of Analytical Chemistry.2015; 2015:1-9.

  • 11. Rohin M Anurag SR. quality by design: an overview of the basic concepts quality by design for biopharmaceuticals. John Wiley & Sons Inc. Publication. Hoboken NJ 20091-20.

  • 12. Phil N Phil JB Tony B Greg M Pauline M. QbD for Better Method Validation and Transfer. http://www.pharmamanufacturing.com/articles/2010/060.html. 2010.

  • 13. George LR Guilong C David TF et al. Reversed-phase liquid chromatographic method development in an analytical quality by design framework. Journal of Liquid Chromatography and Related Technologies. 2013; 36(18): 2612–2638.

  • 14. Bhusnure OG Gandge NV Gholve SB. Sugave BK Giram PS. A Review on Application of Quality by Design Concept to Analytical Method Development. Ijppr.Human 2017; Vol. 10 (1): 63-75.

  • 15. USP Validation and verification expert panel. Lifecycle management of analytical procedures: method development procedure performance qualification and procedure performance verification. United State Pharmacopeial Convention (USP). Pharmacopeial Forum.2013; 39(5).

  • 16. Vogt FG Kord AS. Development of quality-by-design analytical methods. J Pharm Sci. 2011; 100:797-812.

  • 17. Lynn DT. OOS OOT OOC and OOSC. Pharmaceutical Technology. 2011; 35(10):46–47.

  • 18. N. V. V. S. S. Raman Useni RM Hanimi RB.Analytical Quality by Design Approach to Test Method Development and Validation in Drug Substance Manufacturing. Journal of Chemistry. 2015; 2015:1-8.

  • 19. Mayank N Panwar KS Chopra VS Indu B Trivedi P. Quality by design: a systematic approach to pharmaceutical development. Der Pharmacia Lettre. 2010; 2:111-3.

  • 20. ICH. Q8 (R2) Pharmaceutical development. 2009. http://www.ich.org/fileadmin/PublicWebSite/ICHProducts/Guidelines/Quality/Q8R1/Step4/Q8R2Guideline.pdf. Accessed 26 April 2013.

  • 21. Bettencourt DS. Bulska E Godlewska-Żyłkiewicz B et al. Analytical measurement: measurement uncertainty and statistics European Commission -Joint Research Centre Luxembourg Publications Office of the European Union2013: 19-85.

  • 22. USP Validation and verification expert panel. Analytical target profile: Structure and Application throughout the analytical lifecycle. United State Pharmacopeial Convention (USP). Pharmacopeial Forum.2016; 42 (5).

  • 23. USP Validation and verification expert panel. Measurement Uncertainty for the Pharmaceutical Industry. Pharmacopeial Forum. 2018; 44(1).

  • 24. Quality Risk Management Q9 ICH Harmonised Tripartite Guideline 2005.

  • 25. David V Miroslav K. selected overview of risk assessment techniques Problemy eksploatacji. 2009:19-32.

  • 26. Balaji J Murugesh S. Analytical Quality by Design – A Legitimate Paradigm for Pharmaceutical Analytical Method Development and Validation. Mechanics Materials Science & Engineering. 2017;9. Doi 10.2412/mmse.96.97.276

  • 27. Varanasi UB B. D. C. N. Prasad. A Framework for Auditing the Evaluation of Uncertainty for Compliance in Information Systems. Lecture Notes on Software Engineering.2015; 3(1).

  • 28. Deviation Handling and Quality Risk Management World Health Organization (WHO) A note for guidance for the manufacture of prequalified vaccines for supply to United Nations agencies Geneva Switzerland July 2013.

  • 29. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Analytical Procedures and Methods Validation for Drugs and Biologics Guidance for Industry.July 2015.

  • 30. Mogal V Dusane J Borase P Thakare P Kshirsagar S. A review on quality by design Mogal V. et al. Pharmaceutical and Biological Evaluations 2016; vol. 3 (3): 313-319.

  • 31. Meitz A Sagmeister P Langemann T Herwig C. An Integrated Downstream Process Development Strategy along QbD Principles Bioengineering 2014; 1 213-230.

  • 32. Kochling J Wu W Hua Y Guan Q Castaneda-Merced J. A platform analytical quality by design (AQbD) approach for multiple UHPLC-UV and UHPLC-MS methods development for protein analysis. J Pharm Biomed Anal. 2016; 125:130-9.

  • 33. Priyanka PP Sadikali FS Machindra JC Sanjay RC. Quality by design in analytical method development and validation. Journal of Environment and Life Science.2017;2:39-45.

  • 34. M. Deepa K. Ravindra Reddy S. V. Satyanarayana. A Review on Quality by Design Approach for Analytical Method Development. Journal of Pharmacy Research 2017;11(4):272-277.

  • 35. U.S. Food and Drug Administration CDER. Guidance for industry: PAT—a framework for innovative pharmaceutical development manufacturing and quality assurance. 2004.

  • 36. Yu LX Amidon G Khan MA Hoag SW Polli J Raju GK Woodcock J. Understanding Pharmaceutical Quality by Design. AAPS J.2014;16(4): 771–783.

  • 37. USP Validation and verification expert panel. Analytical Control Strategy. United State Pharmacopeial Convention (USP). Pharmacopeial Forum.2016; 42(5).

  • 38. Quality assurance of pharmaceuticals: a compendium of guidelines and related materials. Vol. 2 Good manufacturing practices and inspection. – 2nd ed.

  • 39. Le Blond D. Weitzel J. Burdick R. Analytical Quality by Design Approach to the Development Stage in the Lifecycle of an Analytical Procedure. web’ Institute of Validation Technology IVT Network. 2017

  • 40. Karmarkar S Garber R Genchanok Y George S Yang X Hammond R. Quality by design (QbD) based development of a stability indicating HPLC method for drug and impurities. J Chromatogr. Sci.2011;49(6):439-46.

Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 312 312 52
PDF Downloads 284 284 57